Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesPharmacotherapy for Cannabis Dependence: How Close Are We
CNS Drugs, 06/29/09
Vandrey R et al. - Results from controlled laboratory studies and small open-label clinical studies indicate that buspirone, dronabinol, fluoxetine, lithium and lofexidine may have therapeutic benefit for those seeking treatment for cannabis-related problems. However, controlled clinical trials have not been conducted and are needed to both confirm the potential clinical efficacy of these medications and to validate the laboratory models being used to study candidate medications.
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression
Journal of Psychiatric Practice, 09/29/09
Today in Substance Abuse...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Adverse health effects of non-medical cannabis use
The Lancet, 10/19/09
Improving Clinical Outcomes in Treating Heroin Dependence: Randomized, Controlled Trial of Oral or Implant Naltrexone
Archives of General Psychiatry, 10/09/09
Sponsor
Article Search
Sponsor